- Marketwired•11 days ago
Theratechnologies Inc. today announced that the abstract for the primary end-point results of the ibalizumab phase III study has been selected for a late breaker oral presentation at the IDWeek Conference ...
- Capital Cube•last month
Click here to see latest analysisCapitalcube gives Theratechnologies, Inc. a score of 91.Our analysis is based on comparing Theratechnologies, Inc. with the following peers – Aeterna Zentaris Inc., Nuvo Pharmaceuticals Inc., Cynapsus Therapeutics Inc., Cipher Pharmaceuticals Inc., ProMetic Life Sciences Inc., Telesta Therapeutics Inc., DiaMedica Inc., Transition Therapeutics Inc., Intellipharmaceutics International Inc. and BELLUS Health […] (Read more...) The post Theratechnologies, Inc. – Value Analysis (TORONTO:TH) : July 20, 2016 appeared first on CapitalCube.
- Capital Cube•last monthTheratechnologies, Inc. breached its 50 day moving average in a Bullish Manner : TH-CA : July 19, 2016
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Theratechnologies, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBullish50 Day Moving Average above/below 200 Day Moving AverageBullishRSI […] (Read more...) The post Theratechnologies, Inc. breached its 50 day moving average in a Bullish Manner : TH-CA : July 19, 2016 appeared first on CapitalCube.
Theratechnologies Inc. (TH.TO)
Toronto - Toronto Delayed Price. Currency in CAD
|Day's Range||2.56 - 2.57|
|52wk Range||1.26 - 3.74|
|1y Target Est||N/A|
|P/E Ratio (ttm)||232.73|
|Avg Vol (3m)||299,304|
|Dividend & Yield||N/A (N/A)|